...read the wave

Nano Biz...in depth... im detail


Elan and Roche Expand Nanocrystal Technology License

Proprietary Elan Technology Helps Improve Drug Delivery by
Transforming Drugs into More Effective and "User Friendly" Dosage
Forms to Increase Patient Convenience and Compliance

Elan Corporation, plc today announced a broad license agreement with Roche around Elan's proprietary NanoCrystal(R) technology. The agreement will provide Roche with access to NanoCrystal technology and the right to apply it to a number of proprietary drug candidates. Elan will receive development milestones and royalties on sales of any product incorporating the use of NanoCrystal technology.

Paul Breen, Executive Vice President, Global Services & Operations, Elan said, "We are very pleased to broaden our license agreement with Roche. This agreement highlights the robustness of the technology and the interest of pharmaceutical companies to use this technology. This past year saw the third product launched in the US incorporating our NanoCrystal technology. This agreement brings to a close a very successful year for Elan's drug delivery efforts."

"We are pleased to add this technology to our formulation development options and are enthusiastic about its drug delivery potential," said Ursula Redeker, Roche's Global Head of Safety & Technical Sciences. "This agreement further strengthens our ability to deliver value for patients as we continue to develop innovative, differentiated medicines."

About Elan's NanoCrystal Technology

NanoCrystal technology is designed to enhance the clinical performance of poorly water-soluble drugs by transforming them into nanometer-sized particles. The technology allows the drug to dissolve faster and more completely in the gastrointestinal tract, enabling it to be more easily absorbed by the body. The NanoCrystal technology can be incorporated into all dosage forms both parenteral and oral; including solid, liquid, fast-melt, pulsed release and controlled release.

Three pharmaceutical products have been commercialised incorporating NanoCrystal technology, with several additional product launches anticipated over the next two years. Elan's NanoCrystal Technology is protected by more than 130 U.S. and foreign patents and patent applications. More information about Elan's NanoCrystal technology is available at www.elan.com/drugdelivery

About Elan

Elan is a neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing, selling and marketing advanced therapies in neurodegenerative diseases, autoimmune diseases and severe pain. Elan's (NYSE:ELN) shares trade on the New York, London and Dublin Stock Exchanges.


SOURCE: Elan Corporation, plc

Elan Corporation, plc
Emer Reynolds, 353-1-709-4000 / 800-252-3526
Anita Kawatra, 212-407-5740 / 800-252-3526


This story has been adapted from a news release -
Diese Meldung basiert auf einer Pressemitteilung -
Deze tekst is gebaseerd op een nieuwsbericht -



who is reading
the wave ?

missed some news ?
click on archive photo


or how about joining us


or contacting us ?


about us


our mission